Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical characteristics of tumor-induced osteomalacia lesions in the neurocranium and intracranial structures.

Orphanet journal of rare diseases·2026
Same author

Rational Molecular Design of a Multi-Electron Organic Anode via Rapid Microwave Synthesis for Ultrastable NH<sub>4</sub> <sup>+</sup> Storage.

Angewandte Chemie (International ed. in English)·2026
Same author

Low-dose ultra-high-resolution temporal bone imaging using Sn100 kVp photon-counting CT: A comparative study with conventional CT.

European journal of radiology·2026
Same author

Safety of proton pump inhibitors: an overview of systematic reviews and meta-analyses.

BMJ evidence-based medicine·2026
Same author

Surgical Treatment of Lateral Skull Base Tumors Extending to the Craniovertebral Junction.

Head & neck·2026
Same author

Tailoring Supramolecular Polyurethane Featuring Bio-based Rigid-Flexible Segment Hybrids with Intrinsic Photothermal Conversion and Ultraviolet Blocking.

Research (Washington, D.C.)·2026

Related Experiment Video

Updated: May 16, 2025

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.3K

Dual-Mode Treatment of Hepatocellular Carcinoma Using RGD Cyclopeptide-Modified Liposomes Loaded with Ce6/DOX.

Wentao Xu1,2, Jiajia Zheng1,2, Jiaqi Zhang1

  • 1Cancer Center, Department of Interventional Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, 310014, People's Republic of China.

International Journal of Nanomedicine
|April 1, 2025
PubMed
Summary

This study developed a targeted liposome delivery system for liver cancer, combining sonodynamic therapy (SDT) and chemotherapy. The novel cRGD-Lipo@Ce6/DOX nanocomplex demonstrated significant tumor inhibition and excellent biosafety in preclinical models.

Keywords:
dual-modality therapyhepatocellular carcinomaslysosomal escapesonodynamic therapy

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.4K
Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
10:26

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles

Published on: November 1, 2017

8.4K

Related Experiment Videos

Last Updated: May 16, 2025

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.3K
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.4K
Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
10:26

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles

Published on: November 1, 2017

8.4K

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Hepatocellular carcinoma (HCC) is a prevalent global cancer with limited effective treatments.
  • Current therapies offer modest survival benefits, highlighting the need for improved drug delivery systems.
  • Effective drug delivery must enhance target site accumulation, enable selective release, and facilitate lysosomal escape.

Purpose of the Study:

  • To develop and evaluate a novel targeted drug delivery system for HCC.
  • To investigate the synergistic effects of sonodynamic therapy (SDT) and chemotherapy.
  • To assess the therapeutic efficacy and biosafety of the developed nanocomplex in a preclinical HCC model.

Main Methods:

  • Preparation of cRGD-Lipo@Ce6/DOX, a liposome formulation with RGD peptide, Chlorin e6 (Ce6), and doxorubicin (DOX).
  • Analysis of targeting capability and uptake mechanisms using flow cytometry.
  • Evaluation of drug release and subcellular distribution under ultrasound stimulation.
  • Assessment of therapeutic efficacy and biosafety in an HCC subcutaneous tumor-bearing mouse model.

Main Results:

  • The cRGD-Lipo@Ce6/DOX nanocomplex demonstrated enhanced targeting and penetration efficiency for HCC.
  • Sonodynamic therapy (SDT)-generated reactive oxygen species (ROS) promoted non-lysosomal drug release.
  • The combined SDT and chemotherapy achieved a 94% tumor inhibition rate.
  • The treatment exhibited excellent biosafety in the tested mouse model.

Conclusions:

  • The developed dual-modality therapy shows significant potential for HCC treatment.
  • This combination strategy offers a promising new therapeutic option for patients with liver cancer.
  • Targeted drug delivery systems can improve treatment outcomes for challenging cancers like HCC.